Search results
Showing 1 to 15 of 35 results for certolizumab pegol
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis. This drug is for adults who have tried nonsteroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis in adults.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in